OppenheimerFunds
ESPR icon

OppenheimerFunds’s Esperion Therapeutics ESPR Stock Holding History

OppenheimerFunds’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-92,202
Closed -$7.54M – 949
2015
Q2 		$7.54M Buy
92,202
+35,847
+64% +$3.51M 0.01% 798
2015
Q1 		$5.22M Buy
+56,355
New +$3.64M 0.01% 827

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

OppenheimerFunds's ESPR Position: Q3 2015 in Review

OppenheimerFunds sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 92,202 shares — an estimated $7.54M sold.

OppenheimerFunds first reported a position in ESPR in Q1 2015 and held it in 2 quarters. The position peaked at $7.54M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • OppenheimerFunds reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • OppenheimerFunds sold 92,202 Esperion Therapeutics shares in Q3 2015, an estimated $7.54M.
  • OppenheimerFunds first reported a position in Esperion Therapeutics in Q1 2015 and held it in 2 quarters.
  • OppenheimerFunds's Esperion Therapeutics position peaked at $7.54M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on OppenheimerFunds's 13F filing for Q3 2015, filed 6 Nov 2015.